Skip to main content

ARROWHEAD PHARMACEUTICALS INC

For the period ended Jan 26, 2024. Filed Jan 26, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jan 26, 2024 · Filed Jan 26, 2024

ARWR$58.16+1.2%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Board Composition and Nominating Process

The Nomination Committee of the Board annually considers the size, composition and needs of the Board and, as appropriate, recommends the nominees for directors to the Board for approval. The Nomination Committee considers and evaluates suggestions from many sources regarding possible candidates for directors. Below are general criteria for the evaluation of current and proposed directors:

The highest ethical character and shared values with our Code of Corporate Conduct

Reputation, both personal and professional, consistent with our image and reputation

Accomplishment within a candidate’s field, with superior credentials and recognition

Relevant expertise and experience and the ability to offer advice and guidance to the Chief Executive Officer based on such expertise and experience

Independence, without the appearance of any conflict in serving as a Director, and independence of any particular constituency with the ability to represent all stockholders

Ability to exercise sound business judgment

Diversity, reflecting differences in skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender and ethnicity

The Nomination Committee considers the mix of skills and experience among current and prospective directors with a goal of assembling a Board with complementary skills for the benefit of the Company. Listed below are selected key contributions of each current Board member. The table is not intended to be an exhaustive summary of all the contributions of each Board member.

ExpertiseGivenPerryAnzaloneFerrariOlukotunVakienerWaddill
Biopharma Research& DevelopmentXXXXXX
HealthcareXXXXX
Drug DevelopmentXXXXXX
Executive LeadershipXXXXXXX
Public CompanyGovernanceXXXXXX
Accounting/AuditX
Capital MarketsXXXX
CommercialXXXX

Board Diversity Matrix

The Nomination Committee believes that the Board should represent a diverse mix of skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender, and ethnicity. In furtherance of this goal, the Committee is committed to actively seeking out highly qualified diverse candidates (including women and minority candidates) to include in the pool from which Board nominees are chosen, referred to by some as the “Rooney Rule.”

Currently, one of the Company’s directors self-identifies as Black and one is a woman. These are the Board’s two most recent additions, demonstrating the Board’s commitment to diversify as it matures. Provided below is a board diversity matrix chart pursuant to Nasdaq’s Board Diversity Rule.

Board Diversity Matrix (As of January 26, 2024)
Total Number of Directors#7
FemaleMaleNon-BinaryDid Not Disclose Gender
Part I: Gender Identity
Directors1600
Part II: Demographic Background
African American or Black0100
Alaskan Native or Native American0000
Asian0000
Hispanic or Latinx0000
Native Hawaiian or Pacific Islander0000
White1500
Two or More Races or Ethnicities0000
LGBTQ+0
Did Not Disclose Demographic Background0
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.